Cepheid Flu Test Wins First CLIA Waiver For PCR Panel
This article was originally published in The Gray Sheet
FDA granted both a 510(k) clearance and a waiver for point-of-care use to Cepheid’s Xpert Flu +RSV Express test – the first molecular-based, polymerase chain-reaction panel diagnostic to win a CLIA waiver.
You may also be interested in...
Roche Diagnostics was recently granted a CLIA waiver allowing use of its Cobas Liat System molecular diagnostic to detect over 30 strains of Influenza A/B in doctors' offices and clinics.
Alere’s i Influenza A & B test was granted a CLIA waiver Jan. 6, a step toward moving traditionally complex molecular diagnostics to a wider array of testing settings.
The volume of applications for diagnostic test waivers under the Clinical Laboratory Improvement Amendments increased fivefold in FY 2014, but the total numbers are small, and the change may simply reflect routine year-to-year variation.